Name: REAlease® CD19 MicroBead Kit, human
Availability: InStock

Product data and images for REAlease
^®
CD19 MicroBead Kit
, human

Figures

Figure 1

Step-by-step REAlease MicroBeads separation procedure

Figure 1

Step-by-step REAlease MicroBeads separation procedure

Figure 2

Example of a separation using the REAlease^® CD19 MicroBead Kit

A) CD19

⁺

cells were isolated from human PBMCs using the REAlease

^®

CD19 MicroBead Kit, MS Columns, and a MiniMACS™ Separator. Cells were fluorescently stained with CD19-PE and analyzed by flow cytometry using the MACSQuant

^®

Analyzer X. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

B) The efficient removal of all labels was shown by using Anti-Biotin-APC to analyze the cells by flow cytometry for the presence of REAlease Biotin Complex. Directly after isolation, the cells showed staining of biotin ("MicroBead-free CD19

⁺

cells"), whereas the label-free CD19

⁺

cells after the REAlease Biotin Complex release were negative for biotin similar to the non-labeled cells before separation.

Release efficiency was higher than 99% for the REAlease Anti-Biotin MicroBeads (CD19).

A) Cell purity

Before separation	Label-free CD19 ⁺ cells
View details REAlease ^® CD19 MicroBead Kit , human Figure 2 Example of a separation using the REAlease^® CD19 MicroBead Kit A) CD19 ⁺ cells were isolated from human PBMCs using the REAlease ^® CD19 MicroBead Kit, MS Columns, and a MiniMACS™ Separator. Cells were fluorescently stained with CD19-PE and analyzed by flow cytometry using the MACSQuant ^® Analyzer X. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. B) The efficient removal of all labels was shown by using Anti-Biotin-APC to analyze the cells by flow cytometry for the presence of REAlease Biotin Complex. Directly after isolation, the cells showed staining of biotin ("MicroBead-free CD19 ⁺ cells"), whereas the label-free CD19 ⁺ cells after the REAlease Biotin Complex release were negative for biotin similar to the non-labeled cells before separation. Release efficiency was higher than 99% for the REAlease Anti-Biotin MicroBeads (CD19).	View details REAlease ^® CD19 MicroBead Kit , human Figure 2 Example of a separation using the REAlease^® CD19 MicroBead Kit A) CD19 ⁺ cells were isolated from human PBMCs using the REAlease ^® CD19 MicroBead Kit, MS Columns, and a MiniMACS™ Separator. Cells were fluorescently stained with CD19-PE and analyzed by flow cytometry using the MACSQuant ^® Analyzer X. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. B) The efficient removal of all labels was shown by using Anti-Biotin-APC to analyze the cells by flow cytometry for the presence of REAlease Biotin Complex. Directly after isolation, the cells showed staining of biotin ("MicroBead-free CD19 ⁺ cells"), whereas the label-free CD19 ⁺ cells after the REAlease Biotin Complex release were negative for biotin similar to the non-labeled cells before separation. Release efficiency was higher than 99% for the REAlease Anti-Biotin MicroBeads (CD19).
B) Label-free cells: REAlease Biotin Complex release
Before separation	MicroBead-free CD19 ⁺ cells	Label-free CD19 ⁺ cells
View details REAlease ^® CD19 MicroBead Kit , human Figure 2 Example of a separation using the REAlease^® CD19 MicroBead Kit A) CD19 ⁺ cells were isolated from human PBMCs using the REAlease ^® CD19 MicroBead Kit, MS Columns, and a MiniMACS™ Separator. Cells were fluorescently stained with CD19-PE and analyzed by flow cytometry using the MACSQuant ^® Analyzer X. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. B) The efficient removal of all labels was shown by using Anti-Biotin-APC to analyze the cells by flow cytometry for the presence of REAlease Biotin Complex. Directly after isolation, the cells showed staining of biotin ("MicroBead-free CD19 ⁺ cells"), whereas the label-free CD19 ⁺ cells after the REAlease Biotin Complex release were negative for biotin similar to the non-labeled cells before separation. Release efficiency was higher than 99% for the REAlease Anti-Biotin MicroBeads (CD19).	View details REAlease ^® CD19 MicroBead Kit , human Figure 2 Example of a separation using the REAlease^® CD19 MicroBead Kit A) CD19 ⁺ cells were isolated from human PBMCs using the REAlease ^® CD19 MicroBead Kit, MS Columns, and a MiniMACS™ Separator. Cells were fluorescently stained with CD19-PE and analyzed by flow cytometry using the MACSQuant ^® Analyzer X. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. B) The efficient removal of all labels was shown by using Anti-Biotin-APC to analyze the cells by flow cytometry for the presence of REAlease Biotin Complex. Directly after isolation, the cells showed staining of biotin ("MicroBead-free CD19 ⁺ cells"), whereas the label-free CD19 ⁺ cells after the REAlease Biotin Complex release were negative for biotin similar to the non-labeled cells before separation. Release efficiency was higher than 99% for the REAlease Anti-Biotin MicroBeads (CD19).	View details REAlease ^® CD19 MicroBead Kit , human Figure 2 Example of a separation using the REAlease^® CD19 MicroBead Kit A) CD19 ⁺ cells were isolated from human PBMCs using the REAlease ^® CD19 MicroBead Kit, MS Columns, and a MiniMACS™ Separator. Cells were fluorescently stained with CD19-PE and analyzed by flow cytometry using the MACSQuant ^® Analyzer X. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. B) The efficient removal of all labels was shown by using Anti-Biotin-APC to analyze the cells by flow cytometry for the presence of REAlease Biotin Complex. Directly after isolation, the cells showed staining of biotin ("MicroBead-free CD19 ⁺ cells"), whereas the label-free CD19 ⁺ cells after the REAlease Biotin Complex release were negative for biotin similar to the non-labeled cells before separation. Release efficiency was higher than 99% for the REAlease Anti-Biotin MicroBeads (CD19).

Specifications for REAlease
^®
CD19 MicroBead Kit
, human

Overview

The REAlease

^®

CD19 MicroBead Kit has been developed for positive selection of CD19

⁺

B cells from PBMCs. The kit contains an indirect magnetic labeling system for obtaining target cells free of MicroBeads and REAlease Biotin Complex.

Detailed product information

Background information

As a B cell lineage marker, the CD19 antigen is expressed from the early pro-B cell stage to the B cell lymphoblast stage, but the expression is down-regulated upon B cell maturation to plasma cells. The CD19 antigen is further expressed on most malignant B cells and on a subset of follicular dendritic cells.

Downstream applications

Isolation of specific CD19⁺ cell subsets. The selected CD19⁺ cells can be used for positive selection or depletion of B cell populations that express distinct developmental markers, such as CD5 (e.g. B-1 cells), CD27 (e.g. memory B cells), or IgD (e.g. naive B cells). It can be further used for the isolation of activated B cells according to activation markers, e.g., CD25, CD30, CD38, or CD69.
Isolation of CD19⁺ cell subset which needs to be label-free.

Resources for REAlease
^®
CD19 MicroBead Kit
, human

Documents and Protocols

Brochures/posters

REAlease™ Immunomagnetic Separation Technology - Reversible cell labeling for maximal flexibility

Brochures/posters

MACS® Cell Pre-Enrichment for flow sorting and analysis

Data and images